We want to appreciate you and the author(s) of the manuscript who had precisely read our article by Mansourian et al. (1) titled "Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/ less than 30%)" published in Anatol J Cardiol 2014 Dec 31, (1). The results that are mentioned in the tables of the article are the same as those that had been carefully collected. Considering that this study was a randomized controlled trial, which is the gold standard of clinical research, we had seriously considered the randomization or allocation rules. We paid attention to some different values; therefore, we have considered it in our statistical analysis, and we conducted our analysis for the changes between the groups and not just for the crude results. This has also been indicated under the title of "Study Limitations" in the article. Moreover, the patients in the two groups did not show significant statistical differences among their major coronary artery disease (CAD) risk factors, including hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking. These parameters were eliminated from the tables just for simplicity. Furthermore, all the patients were under similar medication protocols in terms of antihyperlipidemic, antiplatelet, and anticoagulant use. I hope that these explanations are now clear and can resolve the gray areas. Preoperative oral pentoxifylline in case of coronary artery bypass grafting with left ventricular dysfunction (ejection fraction equal to/less than 30%). Anatol J Cardiol 2014 Dec 31.
